Wendell Yarbrough, MD, MMHC, FACS

Professor of Surgery (Otolaryngology) and of Pathology; Section Chief, Otolaryngology; Co-Director Molecular Virology Research Program; Director, Head & Neck Cancer Program, Smilow Cancer Hospital

Physician Biography

My practice focuses on surgery for head and neck cancers including those of the mouth, throat, voicebox, nasal cavity, salivary glands neck, and thyroid glands. We provide multi-specialty care, since patients with head and neck cancers do better when treated by teams of doctors to offer personalized therapy plans. I perform minimally invasive procedures using robots and lasers, as well as more traditional surgeries. Our team is able to provide all aspects of care including reconstructive surgery designed to provide the best cosmetic and functional outcomes. Our team also provides radiation and chemotherapy that can be used after surgery for high risk patients or as a definitive treatment to avoid surgery.

Clinical Interests

  • Clinical Trials as Topic
  • Ear Neoplasms
  • Head and Neck Neoplasms
  • Laryngeal Neoplasms
  • Mouth Neoplasms
  • Neoplasms
  • Neoplasms, Glandular and Epithelial
  • Neoplasms, Unknown Primary
  • Otolaryngology
  • Otorhinolaryngologic Neoplasms
  • Parathyroid Neoplasms
  • Pharyngeal Neoplasms
  • Sarcoma
  • Skin Neoplasms
  • Thyroid Neoplasms
  • Tracheal Neoplasms
  • Early Detection of Cancer
  • Vocal Cord Dysfunction

Patient Care

Accepts new patients? Yes
Patient Type: Adult; Adolescent; Child; Geriatric
Referrals: From patients or physicians

Patient Care Organizations

Surgery: Otolaryngology: Head & Neck Cancer Program

Pathology

Yale Cancer Center: Head & Neck Cancers Program

Yale Medicine

Clinical Trials

Conditions Study Title
Soft Tissue Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combination In Previously Treated Locally Advanced or Metastatic Cervical or HPV+ Head & Neck Cancer
Larynx, Lip, Oral Cavity and Pharynx A Randomized Phase III Study of Pembrolizumab Given Concomitantly With Chemoradiation and as Maintenance Therapy Versus Chemoradiation Alone in Subjects With Locally Advanced Head and Neck Squamous Cell Carcinoma (KEYNOTE-412)
Phase I An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Larynx, Lip, Oral Cavity and Pharynx Phase 1b/2 Trial of IPH2201 And Cetuximab in Patients With Human Papillomavirus (HPV) (+) and HPV (-) Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Lip, Oral Cavity and Pharynx, Soft Tissue A Phase II Study of Enzalutamide (NSC# 766085) for Patients With Androgen Receptor Positive Salivary Cancers
Larynx, Lip, Oral Cavity and Pharynx Single-Arm Phase II Trial of Dual Inhibition of EGFR With Afatinib and Cetuximab With Correlative Studies in the Second-Line Treatment of Recurrent or Metastatic Squamous Cell Cancers of the Head and Neck
Lip, Oral Cavity and Pharynx A Two-arm, Open-label, Randomized Phase II Study of Pembrolizumab (MK-3475) Monotherapy Versus Standard Chemotherapy in Platinum Pre-treated, Recurrent or Metastatic Nasopharyngeal Cancer (NPC) (Keynote-122)
Larynx, Lip, Oral Cavity and Pharynx, Ill-Defined Sites A Phase II Study of Pembrolizumab for Patients With Head and Neck Squamous Cell Carcinoma With Residual Disease Following Definitive Chemoradiation
Lip, Oral Cavity and Pharynx Window Trial 5-aza in HNSCC, T-tare
Lip, Oral Cavity and Pharynx Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

Edit this profile